Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study

• DOI: 10.1007/s00277-020-04045-y
• Publication Date: 2020-06-01T08:02:26Z
• Authors: Jeremie Zerbit; Sylvie Chevret; Sophie Bernard; Marie Kroemer; Charlotte Ablard; Stephanie Harel; Pauline Brice; Isabelle Madelaine; Catherine Thieble...
• Keywords: Hematology

Ibrutinib treatment has been shown to increase survival in patients with B cell malignancies. Real-life data suggest a large part of discontinuations are due toxicities, impairing ibrutinib efficacy. We aimed assess the impact pharmaceutical care program on efficacy and safety ibrutinib. This single-center, cohort, observational study enrolled Patients were either assigned or receive usual care, based physician decision. The was conducted by clinical pharmacists specializing oncology included patient education for management adherence monitoring, interventions reduce drug-drug interactions, follow-up transition from hospital community. Between February 2014 May 2017, we 155 patients, including 42 (27%) who allocated group 113 (73%) group. effect beneficial terms time failure (p = 0.0005). 30-month progression-free overall survivals significantly superior (respectively p 0.002 0.004). Grade 3 higher adverse events occurred more frequently (15%) than (8%). A provides personalized environment outpatient monitoring control key risks associated oral anticancer agents. shows evidence that results significant improvement better tolerance care.